CAMP4 Therapeutics Corporation Increase (Decrease) in Contract with Customer, Liability
CAMP4 Therapeutics Corporation (CAMP) reported Increase (Decrease) in Contract with Customer, Liability of -$2.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$1.78M.
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$1.21M.
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $17.50M, a 4445.45% increase year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $0.00.
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for fiscal 2025 was $17.11M, a 4345.45% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for fiscal 2024 was $385.00K.
- CAMP4 Therapeutics Corporation increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.99M 10-Q · filed 2026-08-13 | $14.51M derived: sum of 3 quarters · filed 2026-08-13 | $14.51M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.21M 10-Q · filed 2026-05-07 | $16.29M derived: sum of 2 quarters · filed 2026-05-07 | $16.29M derived: sum of 3 quarters · filed 2026-05-07 | $16.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $17.50M derived: sum of 2 quarters · filed 2026-03-05 | $17.50M derived: sum of 3 quarters · filed 2026-08-13 | $17.11M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | -$385.00K 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$385.00K 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$385.00K 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $385.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $385.00K derived: sum of 2 quarters · filed 2026-03-05 | $385.00K derived: sum of 3 quarters · filed 2026-03-05 | $385.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |